{
    "id": "wrong_mix_property_subsidiary_00045_1",
    "rank": 24,
    "data": {
        "url": "https://friendsofcancerresearch.org/breakthrough-therapies/",
        "read_more_link": "",
        "language": "en",
        "title": "Friends of Cancer Research",
        "top_image": "https://friendsofcancerresearch.org/wp-content/uploads/opengraph-friends-1.jpg",
        "meta_img": "https://friendsofcancerresearch.org/wp-content/uploads/opengraph-friends-1.jpg",
        "images": [
            "https://friendsofcancerresearch.org/wp-content/uploads/pfp-logo.svg",
            "https://friendsofcancerresearch.org/wp-content/uploads/project-teach-logo.svg",
            "https://friendsofcancerresearch.org/wp-content/uploads/FoCR.svg",
            "https://friendsofcancerresearch.org/wp-content/uploads/pfp-logo.svg",
            "https://friendsofcancerresearch.org/wp-content/uploads/project-teach-logo.svg",
            "https://friendsofcancerresearch.org/wp-content/uploads/FoCR.svg",
            "https://friendsofcancerresearch.org/wp-content/uploads/logo.svg",
            "https://friendsofcancerresearch.org/wp-content/uploads/candid-seal-platinum-2024-150x150.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2021-02-11T17:43:50+00:00",
        "summary": "",
        "meta_description": "The Breakthrough therapies chart is a list of all publicly announced breakthrough therapy designations since the program’s inception in 2012. The chart is updated daily and includes information about each individual agent or trade name of a drug or treatment, the sponsor company, the date of the designation’s public disclosure, the individual agent’s indication, or…",
        "meta_lang": "en",
        "meta_favicon": "https://friendsofcancerresearch.org/wp-content/uploads/logo.svg",
        "meta_site_name": "Friends of Cancer Research",
        "canonical_link": "https://friendsofcancerresearch.org/breakthrough-therapies/",
        "text": "Trade Name (Agent): Atacicept\n\nSponsor: Vera Therapeutics\n\nDate of BT Designation Disclosure: 5/28/2024\n\nIndication: Treatment of IgA nephropathy (IgAN).\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): inavolisib (GDC-0077) + palbociclib (Ibrance) and fulvestrant\n\nSponsor: Roche\n\nDate of BT Designation Disclosure: 5/21/2024\n\nIndication: Treatment of PIK3CA-mutated breast cancer.\n\nCategory: Cancer\n\nTrade Name (Agent): Larsucosterol\n\nSponsor: DURECT Corporation\n\nDate of BT Designation Disclosure: 5/21/2024\n\nIndication: Treatment of individuals with severe alcohol-associated hepatitis (AH), an acute form of alcohol-associated liver disease (ALD).\n\nCategory: Other\n\nTrade Name (Agent): NVL-655\n\nSponsor: Nuvalent\n\nDate of BT Designation Disclosure: 5/20/2024\n\nIndication: Treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more ALK tyrosine kinase inhibitors (TKIs).\n\nCategory: Cancer\n\nTrade Name (Agent): Delpacibart Etedesiran (AOC 1001)\n\nSponsor: Avidity Biosciences\n\nDate of BT Designation Disclosure: 5/14/2024\n\nIndication: Investigational treatment for myotonic dystrophy type 1 (DM1)\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Petosemtamab\n\nSponsor: Merus\n\nDate of BT Designation Disclosure: 5/13/2024\n\nIndication: Treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have experienced disease progression following treatment with platinum-based chemotherapy and a PD-L1/PD-1 inhibitor.\n\nCategory: Cancer\n\nTrade Name (Agent): Scemblix® (asciminib)\n\nSponsor: Novartis\n\nDate of BT Designation Disclosure: 5/10/2024\n\nIndication: Treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).\n\nCategory: Cancer\n\nTrade Name (Agent): Diazoxide Choline\n\nSponsor: Soleno Therapeutics\n\nDate of BT Designation Disclosure: 4/30/2024\n\nIndication: Treatment of adults and children ages 4 years and older with genetically confirmed Prader-Willi syndrome (PWS) who have hyperphagia.\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Xolremdi (mavorixafor)\n\nSponsor: X4 Pharmaceuticals\n\nDate of BT Designation Disclosure: 4/29/2024\n\nIndication: Treatment of patients 12 and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): BEQVEZ™ (fidanacogene elaparvovec-dzkt)\n\nSponsor: Pfizer\n\nDate of BT Designation Disclosure: 4/26/2024\n\nIndication: One-Time Gene Therapy for Adults with Hemophilia B\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Anktiva\n\nSponsor: Immunity Bio\n\nDate of BT Designation Disclosure: 4/22/2024\n\nIndication: Treatment of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer\n\nCategory: Cancer\n\nTrade Name (Agent): ENHERTU®\n\nSponsor: AstraZeneca and Daiichi Sankyo Co.\n\nDate of BT Designation Disclosure: 4/5/2024\n\nIndication: HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors\n\nCategory: Cancer\n\nTrade Name (Agent): WINREVAIR™ (sotatercept-csrk)\n\nSponsor: Merck\n\nDate of BT Designation Disclosure: 3/26/2024\n\nIndication: Treatment of Adults with Pulmonary Arterial Hypertension\n\nCategory: Other\n\nTrade Name (Agent): Nipocalimab\n\nSponsor: J&J\n\nDate of BT Designation Disclosure: 3/25/2024\n\nIndication: Treatment of alloimmunized pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN)\n\nCategory: Other\n\nTrade Name (Agent): CYB003\n\nSponsor: Cybin\n\nDate of BT Designation Disclosure: 3/14/2024\n\nIndication: Adjunctive treatment for major depressive disorder (MDD)\n\nCategory: Other\n\nTrade Name (Agent): Lysergide d-tartrate\n\nSponsor: Mind Medicine\n\nDate of BT Designation Disclosure: 3/7/2024\n\nIndication: Treatment of generalized anxiety disorder\n\nCategory: Other\n\nTrade Name (Agent): Ziftomenib\n\nSponsor: Kura Oncology, Inc.\n\nDate of BT Designation Disclosure: 4/2/2024\n\nIndication: Treatment of heavily pretreated patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML)\n\nCategory: Cancer\n\nTrade Name (Agent): Epkinly™ (epcoritamab-bysp)\n\nSponsor: Genmab U.S.\n\nDate of BT Designation Disclosure: 11/27/2023\n\nIndication: Treatment for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received 2 or more lines of systemic therapy.\n\nCategory: Cancer\n\nTrade Name (Agent): Rivfloza (nedosiran)\n\nSponsor: Novo Nordisk\n\nDate of BT Designation Disclosure: 7/15/2019\n\nApproval Date: 10/2/2023\n\nIndication: Treatment for primary hyperoxaluria type 1 in patients aged 9 years and older with relatively preserved kidney function\n\nCategory: Other\n\nTrade Name (Agent): Dupixent (dupilumab)\n\nSponsor: Regeneron Pharmaceuticals, Sanofi\n\nDate of BT Designation Disclosure: 8/1/2023\n\nIndication: Respiratory - Add-on maintenance treatment of adults with uncontrolled chronic obstructive pulmonary disease (COPD) associated with a history of exacerbations and an eosinophilic phenotype\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Leqembi (LECANEMAB-IRMB)\n\nSponsor: Esai\n\nDate of BT Designation Disclosure: 7/2022\n\nApproval Date: 1/6/2023\n\nIndication: Treatment of Alzheimer’s disease\n\nCategory: Other\n\nTrade Name (Agent): Tukysa (Tucatinib)\n\nSponsor: Seagen\n\nDate of BT Designation Disclosure: 7/2022\n\nApproval Date: 1/19/2023\n\nIndication: Treatment for adult patients In combination with trastuzumab with RAS wildtype, HER2-positive, unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy\n\nCategory: Cancer\n\nTrade Name (Agent): Omisirge (omidubicel-onlv)\n\nSponsor: Gamida Cell\n\nDate of BT Designation Disclosure: 4/17/2023\n\nIndication: Treatment of patients with hematologic malignancies who are in need of a hematopoeitic stem cell transplant.\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): VOWST (Fecal Microbiota Spores)\n\nSponsor: Seres Therapeutics, Inc.\n\nDate of BT Designation Disclosure: 4/26/2023\n\nIndication: To prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI).\n\nCategory: Infectious Disease\n\nTrade Name (Agent): Roctavian (valoctocogene roxaparvovec-rvox B)\n\nSponsor: Biomarin Pharmaceutical Inc.\n\nDate of BT Designation Disclosure: 6/29/2023\n\nIndication: For the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity <1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA approved test.\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Abrysvo (Respiratory Syncytial Virus Vaccine)\n\nSponsor: Pfizer Inc.\n\nDate of BT Designation Disclosure: 3/2/2022\n\nApproval Date: 8/1/2023\n\nIndication: For the prevention of lower respiratory tract disease and severe lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age by active immunization of pregnant individuals.\n\nCategory: Infectious Disease\n\nTrade Name (Agent): Abrysvo (Respiratory Syncytial Virus Vaccine)\n\nSponsor: Pfizer Inc.\n\nDate of BT Designation Disclosure: 3/24/2022\n\nApproval Date: 5/31/2023\n\nIndication: For active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older\n\nCategory: Infectious Disease\n\nTrade Name (Agent): IXCHIQ (Chikungunya Vaccine, Live)\n\nSponsor: Valneva Austria GmbH\n\nDate of BT Designation Disclosure: 7/6/2021\n\nApproval Date: 11/9/2023\n\nIndication: For the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older.\n\nCategory: Infectious Disease\n\nTrade Name (Agent): BAY 2927088\n\nSponsor: Bayer\n\nDate of BT Designation Disclosure: 2/26/2024\n\nIndication: Treatment for patients with unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations, and who have received prior systemic therapy\n\nCategory:\n\nTrade Name (Agent): NVL-520\n\nSponsor: Nuvalent\n\nDate of BT Designation Disclosure: 2/27/2024\n\nIndication: Treatment for patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with two or more ROS1 tyrosine kinase inhibitors (TKIs).\n\nCategory: Cancer\n\nTrade Name (Agent): TAGRISSO (osimertinib) + platinum-based chemotherapy\n\nSponsor: AstraZeneca\n\nDate of BT Designation Disclosure: 8/2023\n\nApproval Date: 2/16/2024\n\nIndication: Treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.\n\nCategory: Cancer\n\nTrade Name (Agent): AlphaMedixTM (212Pb-DOTAMTATE)\n\nSponsor: RadioMedix\n\nDate of BT Designation Disclosure: 1/12/2024\n\nIndication: Treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor (SSTR)–expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have not previously received peptide receptor radioligand therapy (PRRT).\n\nCategory: Cancer\n\nTrade Name (Agent): Tibsovo (ivosidenib)\n\nSponsor: Servier Pharmaceuticals\n\nDate of BT Designation Disclosure: 3/26/2019\n\nApproval Date: 10/24/2023\n\nIndication: Treatment for adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.\n\nCategory:\n\nTrade Name (Agent): Nipocalimab\n\nSponsor: J&J\n\nDate of BT Designation Disclosure: 2/9/2024\n\nIndication: Treatment for individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Latozinemab\n\nSponsor: Alector Inc.\n\nDate of BT Designation Disclosure: 2/7/2024\n\nIndication: An investigational human monoclonal antibody designed to block sortilin to elevate progranulin (PGRN) levels for the potential treatment of frontotemporal dementia with a progranulin gene mutation (FTD-GRN)\n\nCategory: Other\n\nTrade Name (Agent): PF614-MPAR\n\nSponsor: Ensysce Biosciences\n\nDate of BT Designation Disclosure: 1/29/2024\n\nIndication: To provide optimal pain relief at prescribed doses yet limit accidental or intentional overdose by ‘shutting down' opioid release if too much active drug is consumed.\n\nCategory:\n\nTrade Name (Agent): Balversa (erdafitinib)\n\nSponsor: J&J\n\nDate of BT Designation Disclosure: 2018\n\nApproval Date: 1/19/2024\n\nIndication: Treatment for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy.\n\nCategory: Cancer\n\nTrade Name (Agent): Cretostimogene Grenadenorepvec\n\nSponsor: CG Oncology\n\nDate of BT Designation Disclosure: 1/3/2024\n\nIndication: Potential therapeutic option in patients with high-risk BCG-unresponsive non–muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 tumors.\n\nCategory: Cancer\n\nTrade Name (Agent): Xolair (omalizumab)\n\nSponsor: Roche\n\nDate of BT Designation Disclosure: 8/12/2018\n\nIndication: Prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies.\n\nCategory: Other\n\nTrade Name (Agent): mRNA-1345\n\nSponsor: Moderna\n\nDate of BT Designation Disclosure: 1/3/2023\n\nIndication: Prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years or older.\n\nCategory: Infectious Disease\n\nTrade Name (Agent): Enhertu (fam-trastuzumab-deruxtecan-nxki)\n\nSponsor: AstraZeneca and Daiichi Sankyo Co.\n\nDate of BT Designation Disclosure: 8/21/2023\n\nIndication: Treatment for patients with HER2-positive metastatic colorectal cancer (mCRC) who have received at least 2 prior lines of therapy.\n\nCategory: Cancer\n\nTrade Name (Agent): Enhertu (fam-trastuzumab-deruxtecan-nxki)\n\nSponsor: AstraZeneca and Daiichi Sankyo Co.\n\nDate of BT Designation Disclosure: 8/21/2023\n\nIndication: Treatment of patients with unresectable or metastatic HER2-positive solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options\n\nCategory: Cancer\n\nTrade Name (Agent): Epkinly™ (epcoritamab-bysp)\n\nSponsor: AbbVie Inc.\n\nDate of BT Designation Disclosure: 11/27/2023\n\nIndication: Treatment of Relapsed/Refractory Follicular Lymphoma\n\nCategory: Cancer\n\nTrade Name (Agent): BMS-986278\n\nSponsor: Bristol-Myers Squibb Co.\n\nDate of BT Designation Disclosure: 10/24/2023\n\nIndication: A potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF)\n\nCategory: Other\n\nTrade Name (Agent): AST2818 (furmonertinib)\n\nSponsor: ArriVent Biopharma\n\nDate of BT Designation Disclosure: 10/30/2023\n\nIndication: For use as a potential therapeutic option in patients with previously untreated, locally advanced or metastatic nonsquamous non–small cell lung cancer harboring EGFR exon 20 insertion mutations.\n\nCategory: Cancer\n\nTrade Name (Agent): Eflornithine (DFMO)\n\nSponsor: US WorldMeds LLC\n\nDate of BT Designation Disclosure: 4/3/2020\n\nApproval Date: 12/13/2023\n\nIndication: To reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.\n\nCategory: Cancer\n\nTrade Name (Agent): Keytruda (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)\n\nSponsor: Astellas Pharma US, Inc., Merck & Co., Inc.\n\nDate of BT Designation Disclosure: 4/3/2023\n\nApproval Date: 12/15/2023\n\nIndication: Treatment for patients with locally advanced or metastatic urothelial cancer (la/mUC).\n\nCategory: Cancer\n\nTrade Name (Agent): WELIREG™ (belzutifan)\n\nSponsor: Merck & Co., Inc.\n\nDate of BT Designation Disclosure: 12/14/2023\n\nIndication: Treatment for patients with renal cell carcinoma who have received prior treatment.\n\nCategory: Cancer\n\nTrade Name (Agent): VT-X7\n\nSponsor: Osteal Therapeutics\n\nDate of BT Designation Disclosure: 12/5/2023\n\nIndication: A drug-device combination for periprosthetic joint infection in hip and knee replacement patients\n\nCategory: Other\n\nTrade Name (Agent): Crinecerfont\n\nSponsor: Neurocrine Biosciences Inc.\n\nDate of BT Designation Disclosure: 12/6/2023\n\nIndication: Treatment of congenital adrenal hyperplasia\n\nCategory: Other\n\nTrade Name (Agent): Cretostimogene Grenadenorepvec\n\nSponsor: CG Oncology\n\nDate of BT Designation Disclosure: 12/5/2023\n\nIndication: Immunotherapy for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.\n\nCategory: Cancer\n\nTrade Name (Agent): Pegozafermin\n\nSponsor: 89bio\n\nDate of BT Designation Disclosure: 12/4/2023\n\nIndication: Treatment of nonalcoholic steatohepatitis (NASH) with fibrosis\n\nCategory: Other\n\nTrade Name (Agent): TAR-200\n\nSponsor: J&J\n\nDate of BT Designation Disclosure: 12/4/2023\n\nIndication: Potential future treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for or elected not to undergo radical cystectomy (surgical removal of the bladder)\n\nCategory: Cancer\n\nTrade Name (Agent): Opfolda™ (miglustat)\n\nSponsor: Amicus Therapeutics\n\nDate of BT Designation Disclosure: 2019\n\nApproval Date: 9/28/2023\n\nIndication: In combination with Opfolda, for the treatment of adult patients with late onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT)\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Pombiliti™ (cipaglucosidase alfa-atga)\n\nSponsor: Amicus Therapeutics\n\nDate of BT Designation Disclosure: 2019\n\nApproval Date: 9/28/2023\n\nIndication: In combination with Opfolda, for the treatment of adult patients with late onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT)\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Pegozafermin\n\nSponsor: 89bio\n\nDate of BT Designation Disclosure: 9/21/2023\n\nIndication: Nonalcoholic Steatohepatitis (NASH)\n\nCategory: Other\n\nTrade Name (Agent): INO-3107\n\nSponsor: INOVIO Pharmaceuticals Inc.\n\nDate of BT Designation Disclosure: 9/7/2023\n\nIndication: Treatment for patients with Recurrent Respiratory Papillomatosis (RRP)\n\nCategory: Cancer\n\nTrade Name (Agent): NS-089/NCNP-02\n\nSponsor: NS Pharma\n\nDate of BT Designation Disclosure: 7/27/2023\n\nIndication: Investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.\n\nCategory: Other\n\nTrade Name (Agent): RBT-1\n\nSponsor: Renibus Therapeutics\n\nDate of BT Designation Disclosure: 7/11/2023\n\nIndication: Reduction in risk of post-operative complications in patients undergoing cardiothoracic surgery\n\nCategory: Other\n\nTrade Name (Agent): Zenocutuzumab (Zeno)\n\nSponsor: Merus N.V.\n\nDate of BT Designation Disclosure: 6/29/2023\n\nIndication: Treatment of patients with advanced unresectable or metastatic NRG1 fusion (NRG1+) pancreatic cancer following progression with prior systemic therapy or who have no satisfactory alternative treatment options.\n\nCategory: Cancer\n\nTrade Name (Agent): PRGN-2012 AdenoVerse™\n\nSponsor: Precigen\n\nDate of BT Designation Disclosure: 6/20/2023\n\nIndication: Treatment of recurrent respiratory papillomatosis (RRP).\n\nCategory: Other\n\nTrade Name (Agent): Resiniferatoxin (RTX)\n\nSponsor: Grünenthal\n\nDate of BT Designation Disclosure: 5/22/2023\n\nIndication: Treatment for pain associated with osteoarthritis (OA) of the knee.\n\nCategory: Other\n\nTrade Name (Agent): Spesolimab\n\nSponsor:\n\nDate of BT Designation Disclosure: 5/2/2023\n\nIndication: Investigational treatment for the prevention of flares in adults with generalized pustular psoriasis (GPP).\n\nCategory: Other\n\nTrade Name (Agent): SAB-176\n\nSponsor: SAB Biotherapeutics\n\nDate of BT Designation Disclosure: 4/18/2023\n\nIndication: Therapeutic for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains.\n\nCategory: Infectious Disease\n\nTrade Name (Agent): Resmetirom\n\nSponsor: Madrigal Pharmaceuticals\n\nDate of BT Designation Disclosure: 4/18/2023\n\nIndication: Treatment of patients with NASH with liver fibrosis.\n\nCategory: Other\n\nTrade Name (Agent): mRNA-4157/V940 in combination with KEYTRUDA\n\nSponsor: Merck, Moderna\n\nDate of BT Designation Disclosure: 2/22/2023\n\nIndication: Adjuvant treatment of patients with high-risk melanoma following complete resection.\n\nCategory: Cancer\n\nTrade Name (Agent): Pimicotinib (ABSK021)\n\nSponsor: Abbisko Therapeutics\n\nDate of BT Designation Disclosure: 1/30/2023\n\nIndication: 1/30/2023\n\nCategory: Other\n\nTrade Name (Agent): mRNA-1345\n\nSponsor: Moderna\n\nDate of BT Designation Disclosure: 1/30/2023\n\nIndication: Vaccine for respiratory syncytial virus (RSV)\n\nCategory: Infectious Disease\n\nTrade Name (Agent): VAX-24\n\nSponsor: Vaxcyte\n\nDate of BT Designation Disclosure: 1/5/2023\n\nIndication: Investigational 24-valent pneumococcal conjugate vaccine (PCV) candidate for the prevention of invasive pneumococcal disease (IPD)\n\nCategory: Infectious Disease\n\nTrade Name (Agent): Pegsitacianine\n\nSponsor: OncoNano Medicine\n\nDate of BT Designation Disclosure: 1/4/2023\n\nIndication: Adjunct for the visualization of metastatic disease in the peritoneal cavity in patients undergoing cytoreductive surgery.\n\nCategory: Cancer\n\nTrade Name (Agent): Adagrasib (KRAZATI™)\n\nSponsor: Mirata Therapeutics Inc.\n\nDate of BT Designation Disclosure: 12/21/2022\n\nIndication: Treatment in combination with cetuximab in patients with KRASG12C-mutated advanced colorectal cancer (CRC) whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.\n\nCategory: Cancer\n\nTrade Name (Agent): Efruxifermin (EFX)\n\nSponsor: Akero Therapeutics\n\nDate of BT Designation Disclosure: 12/7/2022\n\nIndication: Treatment of nonalcoholic steatohepatitis (NASH).\n\nCategory: Other\n\nTrade Name (Agent): Revumenib\n\nSponsor: Syndax\n\nDate of BT Designation Disclosure: 12/4/2022\n\nIndication: Treatment of adult and pediatric patients with relapsed or refractory (R/R) acute leukemia harboring a KMT2A rearrangement (KMT2Ar).\n\nCategory: Cancer\n\nTrade Name (Agent): Zimura (avacincaptad pegol)\n\nSponsor: IVERIC bio\n\nDate of BT Designation Disclosure: 11/17/2022\n\nIndication: Treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).\n\nCategory: Other\n\nTrade Name (Agent): Elranatamab\n\nSponsor: Pfizer Inc.\n\nDate of BT Designation Disclosure: 11/3/2022\n\nApproval Date: 8/14/2023\n\nIndication: Treatment of people with relapsed or refractory multiple myeloma (RRMM).\n\nCategory: Cancer\n\nTrade Name (Agent): Setmelanotide\n\nSponsor: Rhythm Pharmaceutical, Inc.\n\nDate of BT Designation Disclosure: 11/1/2022\n\nIndication: Treatment of hypothalamic obesity.\n\nCategory: Other\n\nTrade Name (Agent): GBS6 (PF-06760805)\n\nSponsor: Pfizer Inc.\n\nDate of BT Designation Disclosure: 9/7/2022\n\nIndication: Vaccine for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy.\n\nCategory: Infectious Disease\n\nTrade Name (Agent): Taletrectinib\n\nSponsor: AnHeart Therapeutics\n\nDate of BT Designation Disclosure: 8/3/2022\n\nIndication: Treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who are ROS1 tyrosine kinase inhibitor (TKI) treatment naïve or previously treated with crizotinib.\n\nCategory: Cancer\n\nTrade Name (Agent): Imcivree (setmelanotide)\n\nSponsor: Rhythm Pharmaceutical, Inc.\n\nDate of BT Designation Disclosure: 1/7/2016\n\nApproval Date: 6/16/2022\n\nIndication: For chronic weight management in adult and pediatric patients 6 years of age and older with Bardet-Biedl Syndrome (BBS).\n\nCategory: Other\n\nTrade Name (Agent): Gedatolisib\n\nSponsor: Celcuity Inc.\n\nDate of BT Designation Disclosure: 7/18/2022\n\nIndication: Treatment of patients with HR+/HER2- metastatic breast cancer whose disease progressed during treatment with a CDK4/6 therapy and a non-steroidal aromatase inhibitor.\n\nCategory: Cancer\n\nTrade Name (Agent): Dupixent (dupilumab)\n\nSponsor: Regeneron Pharmaceuticals Inc.\n\nDate of BT Designation Disclosure: 10/1/2016\n\nApproval Date: 6/7/2022\n\nIndication: Treatment of adult and pediatric patients ages 6 months and older with moderateto-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.\n\nCategory: Other\n\nTrade Name (Agent): VIJOICE (alpelisib)\n\nSponsor: Novartis Pharmaceuticals Corp.\n\nDate of BT Designation Disclosure: 11/13/2019\n\nApproval Date: 4/5/2022\n\nIndication: Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.\n\nCategory: Cancer\n\nTrade Name (Agent): Apretude (Cabotegravir)\n\nSponsor: ViiV Healthcare\n\nDate of BT Designation Disclosure: 11/17/2020\n\nApproval Date: 12/20/2021\n\nIndication: HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and pediatric patients 12 to less than 18 years of age weighing at least 35 kg.\n\nCategory: Infectious Disease\n\nTrade Name (Agent): Oxbryta (voxelotor)\n\nSponsor: Global Blood Therapeutics, Inc.\n\nDate of BT Designation Disclosure: 1/3/2018\n\nApproval Date: 12/17/2021\n\nIndication: Treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Oxbryta (voxelotor)\n\nSponsor: Global Blood Therapeutics, Inc.\n\nDate of BT Designation Disclosure: 1/3/2018\n\nApproval Date: 12/17/2021\n\nIndication: Treatment of sickle cell disease in pediatric patients 4 years of age and older.\n\nCategory: Rare Inherited Disorders\n\nTrade Name (Agent): Orencia (abatacept)\n\nSponsor: Bristol-Myers Squibb Co.\n\nDate of BT Designation Disclosure: 12/4/2019\n\nApproval Date: 12/15/2021\n\nIndication: Prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors.\n\nCategory: Other\n\nTrade Name (Agent): Fyarro (ABI-009)\n\nSponsor: Aadi Bioscience Inc.\n\nDate of BT Designation Disclosure: 1/3/2019\n\nApproval Date: 11/22/2021\n\nIndication: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).\n\nCategory: Cancer\n\nTrade Name (Agent): CARVYKTI (ciltacabtagene autoleucel)\n\nSponsor: Janssen Pharmaceuticals Inc.\n\nDate of BT Designation Disclosure: 2022\n\nApproval Date: 2/28/2022\n\nIndication: Treatment of adult patients with relapsed or refractory multiple myeloma, who previously received a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody.\n\nCategory: Cancer\n\nTrade Name (Agent): Dupixent (dupilumab)\n\nSponsor: Regeneron Pharmaceuticals Inc.\n\nDate of BT Designation Disclosure: 9/14/2020\n\nApproval Date: 5/20/2022\n\nIndication: Treatment of patients 12 years and older with eosinophilic esophagitis (EoE).\n\nCategory: Other\n\nTrade Name (Agent): Tecartus (brexucabtagene autoleuce)\n\nSponsor: Kite Pharma Inc.\n\nDate of BT Designation Disclosure: 2016\n\nApproval Date: 7/24/2020\n\nIndication: Chimeric antigen receptor or CAR T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma or MCL.\n\nCategory: Cancer\n\nTrade Name (Agent): Talquetamab\n\nSponsor: Janssen Pharmaceuticals Inc.\n\nDate of BT Designation Disclosure: 6/29/2022\n\nApproval Date: 8/9/2023\n\nIndication: Treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.\n\nCategory: Cancer\n\nTrade Name (Agent): Inaxaplin (VX-147)\n\nSponsor: Vertex Pharmaceuticals, Inc.\n\nDate of BT Designation Disclosure: 6/8/2022\n\nIndication: Treatment for APOL1-mediated focal segmental glomerulosclerosis (FSGS).\n\nCategory: Other\n\nTrade Name (Agent): Efanesoctocog alfa\n\nSponsor: Sanofi, Sobi\n\nDate of BT Designation Disclosure: 6/1/2022\n\nIndication: Treatment of people with hemophilia A.\n\nCategory: Other\n\nTrade Name (Agent): TMB-001\n\nSponsor: Timber Pharmaceuticals, Inc.\n\nDate of BT Designation Disclosure: 5/31/2022\n\nIndication: Treatment of congenital ichthyosis (CI).\n\nCategory: Other\n\nTrade Name (Agent): Repotrectinib\n\nSponsor: Turning Point Therapeutics Inc.\n\nDate of BT Designation Disclosure: 5/10/2022\n\nIndication: Treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with one ROS1 tyrosine kinase inhibitor and who have not received prior platinum-based chemotherapy.\n\nCategory: Cancer\n\nTrade Name (Agent): ENHERTU (fam-trastuzumab deruxtecan-nxki)\n\nSponsor: AstraZeneca, Daiichi Sankyo\n\nDate of BT Designation Disclosure: 4/26/2022\n\nApproval Date: 5/4/2022\n\nIndication: Treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.\n\nCategory: Cancer\n\nTrade Name (Agent): CMS I-neb\n\nSponsor: Zambon\n\nDate of BT Designation Disclosure: 4/21/2022\n\nIndication: Treatment for the reduction in the incidence of pulmonary exacerbations in adult patients with non-cystic fibrosis bronchiectasis (NCFB) colonized with P. aeruginosa.\n\nCategory: Other\n\nTrade Name (Agent): V116\n\nSponsor: Merck & Co., Inc.\n\nDate of BT Designation Disclosure: 4/14/2022\n\nIndication: Vaccine for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older.\n\nCategory: Infectious Disease\n\nTrade Name (Agent): EDSIVO™ (celiprolol)\n\nSponsor: Acer Therapeutics Inc.\n\nDate of BT Designation Disclosure: 4/4/2022\n\nIndication: Treatment of patients with COL3A1-positive vascular Ehlers-Danlos syndrome (vEDS).\n\nCategory: Other"
    }
}